Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -4915.19%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-4915.19%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Attovia Therapeutics, Inc.
Market Cap
$774.32M
EBITDA Margin
-4915.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$775.72M
EBITDA Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$776.24M
EBITDA Margin
-28.62%
TTM Avg
-126.34%
3Y Avg
-26187.68%
5Y Avg
-23869.36%
Market Cap
$780.95M
EBITDA Margin
18.47%
TTM Avg
18.88%
3Y Avg
13.21%
5Y Avg
14.52%
Market Cap
$767.46M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
Market Cap
$786.48M
EBITDA Margin
-14.10%
TTM Avg
-9.55%
3Y Avg
-6.60%
5Y Avg
-0.48%
Market Cap
$749.55M
EBITDA Margin
-27116.80%
TTM Avg
-23848.80%
3Y Avg
-16467.00%
5Y Avg
-16467.00%
Market Cap
$734.10M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $774.32M | -4915.19% | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Geron Corporation (GERN)vs › | $776.24M | -28.62% | -126.34% | -26187.68% | -23869.36% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 18.47% | 18.88% | 13.21% | 14.52% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -14.10% | -9.55% | -6.60% | -0.48% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -27116.80% | -23848.80% | -16467.00% | -16467.00% |
| InMode Ltd. (INMD)vs › | $812.20M | 23.23% | 25.96% | 33.88% | 36.34% |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | 12.02% | 14.44% | -4.83% | -238.26% |
Gross Margin
40.4%
EBITDA Margin
-4915.2%
Operating Margin
-4974.7%
Net Margin
-4490.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -4790.44% |
